Biopharma and Biotherapeutics

When utilizing different cell lines, expression, productivity and upstream process design, in general, need to be adapted to the metabolism and behavior of these cells. Bacterial systems have the advantage of quickly reaching high cell densities but slow when it comes to protein expression. Apart from that, bacterial systems cannot glycosylated proteins which makes them unsuitable for the production of monoclonal antibodies and many therapeutic proteins. There are also big differences when looking at mammalian cells such as CHO and Hybridoma cells. This workshop will discuss the nature of these issues and why they necessitate very different ways of upstream processing.